Perovskite oxides with formula ABO3 or A2BO4 are a very important class of functional materials that exhibit a range of stoichiometries and crystal structures. Because of the structural features, they could accommodate around 90% of the metallic natural elements of the Periodic Table that stand solely or partially at the A and/or B positions without destroying the matrix structure, offering a way of correlating solid state chemistry to catalytic properties. Moreover, their high thermal and hydrothermal stability enable them suitable catalytic materials either for gas or solid reactions carried out at high temperatures, or liquid reactions carried out at low temperatures. In this review, we addressed the preparation, characterization, and application of perovskite oxides in heterogeneous catalysis. Preparation is an important issue in catalysis by which materials with desired textural structure and physicochemical property could be achieved; characterization is the way to explore and understand the textural structures and physicochemical properties of the material; however, application reflects how and where the material could be used and what it can solve in practice, which is the ultimate goal of catalysis. This review is organized in five sections: (1) a brief introduction to perovskite oxides, (2) preparation of perovskite oxides with different textural structures and surface morphologies, (3) general characterizations applied to perovskite oxides, (4) application of perovskite oxides in heterogeneous catalysis, and (5) conclusions and perspectives. We expected that the overview on these achievements could lead to research on the nature of catalytic performances of perovskite oxides and finally commercialization of them for industrial use.

Purpose: To determine the possibility of synergistic antileukemic activity and the underlying molecular mechanisms associated with cytarabine combined with valproic acid (VPA; a histone deacetylase inhibitor and a Food and Drug Administration-licensed drug for treating both children and adults with epilepsy) in pediatric acute myeloid leukemia (AML).Experimental Design: The type and extent of antileukemic interactions between cytarabine and VPA in clinically relevant pediatric AML cell lines and diagnostic blasts from children with AML were determined by MTT assays and standard isobologram analyses. The effects of cytarabine and VPA on apoptosis and cell cycle distributions were determined by flow cytometry analysis and caspase enzymatic assays. The effects of the two agents on DNA damage and Bcl-2 family proteins were determined by Western blotting.Results: We showed synergistic antileukemic activities between cytarabine and VPA in four pediatric AML cell lines and nine diagnostic AML blast samples. t(8;21) AML blasts were significantly more sensitive to VPA and showed far greater sensitivities to combined cytarabine and VPA than non-t(8;21) AML cases. Cytarabine and VPA cooperatively induced DNA double-strand breaks, reflected in induction of γH2AX and apoptosis, accompanied by activation of caspase-9 and caspase-3. Further, VPA induced Bim expression and short hairpin RNA knockdown of Bim resulted in significantly decreased apoptosis induced by cytarabine and by cytarabine plus VPA.Conclusions: Our results establish global synergistic antileukemic activity of combined VPA and cytarabine in pediatric AML and provide compelling evidence to support the use of VPA in the treatment of children with this deadly disease. Clin Cancer Res; 16(22); 5499-510. ©2010 AACR.